Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 26
- Registration Number
- NCT03967522
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France
🇫🇷CHU Besancon, Besançon, France
🇫🇷CHU Bordeaux, Bordeaux, France
Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients
- Conditions
- Glioblastomas
- Interventions
- Diagnostic Test: Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 16
- Registration Number
- NCT03903419
- Locations
- 🇫🇷
Hôpital Pierre WERTHEIMER - HCL, BRON Cedex, France
🇫🇷Centre Léon Berard, Lyon, France
Satisfaction & Efficacy of Compression Using Surgical Gloves in Chemo-induced Peripheral Neuropathies
- Conditions
- Breast CancerColorectal Cancer
- Interventions
- Device: Chilled glovesDevice: Surgical gloves
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 177
- Registration Number
- NCT03872908
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Infirmerie Protestante, Caluire-et-Cuire, France
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
- Conditions
- Adenocarcinoma of the PancreasAdenocarcinoma of the ColonAdenocarcinoma of the Rectum
- Interventions
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 54
- Registration Number
- NCT03871959
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire)
- Conditions
- Breast Cancer
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 40
- Registration Number
- NCT03870802
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
COLON-IM : Microbiota and Immune Infiltrate in Normal, Dysplastic and Neoplastic Colorectal Tissue
- Conditions
- Colorectal Cancer
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 400
- Registration Number
- NCT03841799
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷GARBIT Vincent, Lyon, France
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 33
- Registration Number
- NCT03818061
- Locations
- 🇫🇷
Centre Henri Becquerel, Rouen, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Clinique Mutualiste de l'Estuaire, Saint-Nazaire, France
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
- Conditions
- Breast CancerTriple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 95
- Registration Number
- NCT03818685
- Locations
- 🇫🇷
Hopital Prive Jean Mermoz, Lyon, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Clinique de la Sauvegarde, Lyon, France
Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 35
- Registration Number
- NCT03732495
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷CHU Angers, Angers, France
🇫🇷CHU Bordeaux - Hôpital Saint-André, Bordeaux, France
FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 104
- Registration Number
- NCT03723967
- Locations
- 🇫🇷
Centre Henri Becquerel, Rouen, France
🇫🇷Institut de Cancérologie de Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy, France
🇫🇷Clinique des Ormeaux, Le Havre, France